Phase 4 N=20 Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects
HIV
Primary: Change in Peak Oxygen Uptake. — 2.2; 2.8 ml/Kg/min — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=40 Contralateral Comparison of Three Excimer Laser Systems in Performing LASIK
Myopia · Astigmatism
Primary: 1 Day Postoperative Lasik Uncorrected Visual Acuity — -0.04; -0.05; 0.06 LogMar
Phase 4 N=361 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs
Focal Epilepsy
Primary: 58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment — 0.61; 0.46; 0.56 proportion of participants…
Phase 4 N=7 Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
Continuous Ambulatory Peritoneal Dialysis · End Stage Renal Disease
Primary: Volume of Distribution, Central Compartment (Vc) — 2.78 Liters (L)
Phase 4 N=321 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.
Healthy Subjects
Primary: Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series — 100.0…
Phase 4 N=81 Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated
Glaucoma, Open-Angle
Primary: Change From Baseline in Average Intraocular Pressure (IOP) — 28.4; 28.5; -13.5; -11.4 Millimeters of Mercury (mmHg)
Phase 4 N=1,902 Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III
Heart Disease
Primary: For the Primary Endpoint the Reduction of Ventricular Therapies (ATP and Shocks) Delivered for Treating Fast Spontaneous Arrhythmia Episodes Was Measured. — 67.1; 41.9…
Phase 4 N=331 Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses
Depression
Primary: Inventory of Depressive Symptomatology-Clinician Administered (IDS-C) Mean Change From Baseline to Week 22 of the Acute Phase (ITT Population). — -9.96; -10.29; -10.30…
Phase 4 N=127 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 0 at Hour 16 — 0.62; 1.01; 2.14; 0.93 Scores on a Scale
Phase 4 N=73 Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
Pulmonary Arterial Hypertension
Primary: Number of Adverse Events — 440; 266; 41; 15 number of events
Phase 4 N=108 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Gastroesophageal Reflux Disease · GERD · Reflux Esophagitis
Primary: Change in the Frequency of Heartburn During the 7-day Period Prior to the 8 Week Visit (Visit 3) Compared to the Frequency of Heartburn During the 7-day Period Prior to…
Phase 4 N=291 A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
Bipolar Depression
Primary: Change From Baseline in the Children's Depression Rating Scale Revised (CDRS-R) Total Score at Week 8 — -28.43; -23.40 units on a scale — p=0.003
Phase 4 N=239 Superiority Study for Pain Treatment After Cesarean
Pain
Primary: Difference of Pain Scores on the Visual Analog Scale — 5.88; 4.85 VAS score at 24 hours — p=<0.05
Phase 4 N=820 Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence
Tobacco Use Disorder
Primary: 12 Month Prolonged Abstinence From Tobacco Measured at 12 Months From Completion of Intervention. — 169; 321; 318 participants
Phase 4 N=154 Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors
Fatigue · Iron Deficiency
Primary: Level of Fatigue Before and After Iron Treatment/Placebo, Using a 10 Point Visual Analogue Scale. — 3.4; 3.5 centimeter — p=0.69